Crysvita (burosumab) co-developers Ultragenyx (Nasdaq: RARE) and Kyowa Kirin (TYO: 4151) have submitted to the US regulator for an expanded label.
Following initial approval in FGF23-related hypophosphatemic rickets and osteomalacia, the firms are seeking to market the option for FGF23-related hypophosphatemia associated with phosphaturic mesenchymal tumors (TIO).
If accepted, the US Food and Drug Administration will provide a target action date for the submission next month.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze